Accrelist FY2026 Losses Narrow As Medical Aesthetics Revenue Rises

5 Key Takeaways from Accrelist’s FY2026 Results

Micro-cap companies often struggle with strategic pivots, facing the dual challenge of legacy costs and the high capital requirements of new growth engines. For Accrelist Ltd, these challenges were quantified in FY2025 by massive impairment losses and write-offs totaling over S$3.1 million, representing the significant friction involved in transitioning away from stagnant business models.

The Group is now aggressively leaning into the medical aesthetics sector to overcome these legacy hurdles. Operating under the “A.M Aesthetics” brand, Accrelist manages a chain of registered aesthetic medical clinics in Singapore and Malaysia. While it maintains a 52.5% controlling stake in precision engineering firm Jubilee Industries Holdings Ltd, the Group’s strategic focus has shifted decisively toward high-margin medical services.

The unaudited results for the full year ended 31 March 2026 (FY2026) reveal a business at a critical juncture. While a net loss persists, the underlying data suggests a significant operational turnaround. By analyzing these results, it becomes clear that the business model is reaching an inflection point where operational profitability is beginning to outpace legacy burn.

1. The EBITDA Flip from Red to Green

The most impactful financial metric in the FY2026 report is the reversal of the Group’s Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). In FY2025, the Group reported a negative EBITDA of S4.846 million. In FY2026, this figure shifted to a positive S1.312 million.

This meaningful change represents a fundamental transition from cash-burn to operational profitability. For an investor, moving to positive EBITDA is often the first step toward institutional investability, as it demonstrates that the core business can cover its operating expenses before accounting for non-cash costs and financing.

Operational Performance Shift

2. Aesthetics as the Primary Growth Engine

Data from the segment reporting confirms that Aesthetic Medical Services is the Group’s primary driver, with revenue reaching S15.291 million in FY2026. While management classifies the system distribution, commodities, and fintech business segments as “dormant,” the “Others” reporting line still captured S350,000 in miscellaneous revenue for the year, up from S$18,000 in FY2025.

Effectively, Accrelist has become a concentrated bet on the aesthetics market and precision moulding. The Aesthetic Medical Services business model is particularly attractive for its lack of receivables risk and superior liquidity. Management highlights the following:

“Aesthetic Medical Services is a business where cash is collected from customers upon their visit and with no credit terms, resulting in better cash flow.”

3. Dramatic Reduction in Net Losses and Impairments

The Group’s profit or loss statement shows a sharp 82.8% improvement in the bottom line. The total loss for the year was reduced from S8.058 million in FY2025 to S1.385 million in FY2026.

This improvement is primarily due to a cleaned up balance sheet and the absence of the one-off hits that weighed down the prior year. FY2025 results were heavily impacted by S2.509 million in impairment losses on receivables and S616,000 in bad debt write-offs. These charges did not recur in FY2026, providing a much clearer view of the Group’s actual recurring business performance and its path toward a net profit.

4. The Strategic Weight of Associate Company Results

Beyond its core operations, Accrelist saw a significant increase in the performance of its associated holdings. The share of results from associated companies, which include Honfoong Plastic Industries and McLean Technologies, grew by over 100% to S$845,000 in FY2026.

Notably, this S845,000 contribution from associates is actually larger than the net loss attributable to equity holders of the Company, which stood at S264,000. These associate holdings are currently propping up the Group’s bottom line while the core aesthetics business reaches for its own break-even point. However, investors should note a key risk: these associate results are not yet finalized and remain subject to the completion of audits for both Honfoong and McLean.

5. Navigating the Working Capital Constraints

Despite operational improvements, the Group maintains a negative working capital position of S$0.4 million. Management has justified the Group’s status as a “going concern” by citing the “uptrend” in Aesthetic Medical Services financial performance since FY2024 and the segment’s inherent cash-upfront structure.

From a strategic perspective, this presents a balanced risk-reward profile. The primary risk remains the narrow margin of current assets over current liabilities, which leaves little room for operational error. The potential reward lies in the continued scaling of high-margin medical services, which provide the cash flow necessary to eventually eliminate this working capital deficit.

Closing Thought

While Accrelist remains in a net loss position, the trajectory of the business has fundamentally changed. The move to positive EBITDA and the elimination of heavy impairment losses suggest that the most difficult stage of its corporate transition may be in the rearview mirror.

Is the market currently valuing Accrelist for its precision engineering past, or its high-margin aesthetic future?

Related stories: Mary Chia Pivots To Digital & E-Commerce Following FY2026 Revenue Drop